title: [A case of recurrent pancreatic cancer with lung metastasis responding to S-1 combined gemcitabine chemotherapy].
abstract: The patient was a 54-year-old male. In July 2004, he underwent resection of the pancreatic body tail region to treat pancreatic body tail cancer. On histopathological examination, the stump of the extirpated specimen was positive for tumor cells. After surgery, 10 courses of therapy with gemcitabine hydrochloride(GEM, 1, 000 mg/m(2), 3-week administration followed by 1-week discontinuation)were performed, and follow-up was continued. In February 2006, local relapse was detected. Chemotherapy with GEM was administered for 1 year and 9 months. However, in November 2007, an increase in the recurrent lesion size and right lung metastasis were noted. The regimen was switched to combination therapy with S-1 and GEM(S-1 60 mg/m(2) day, continuous administration on days 1 to 14 and 2-week discontinuation; and GEM 1, 000 mg/ m(2), administered on days 8 and 15). After the end of the 11th course, PET-CT revealed the disappearance of FDG accumulation in the recurrent and metastatic lesion sites. During the treatment period, there were no grade 3 or higher adverse reactions. The patient is being treated at the outpatient clinic (as of January 2009).
authors.affiliation: Dept. of Surgery, Kurashiki Central Hospital.
authors.forename: Ippei
authors.initials: I
authors.lastname: Fukada
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Ikeda
authors.forename: Kazushige
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Michio
authors.initials: M
authors.lastname: Okabe
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tsuruta
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Morimoto
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Kawamoto
authors.forename: Kaoru
authors.initials: K
authors.lastname: Sano
authors.forename: Tebun
authors.initials: T
authors.lastname: Paku
authors.forename: Shiro
authors.initials: S
authors.lastname: Imai
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ito
authors.forename: Keizo
authors.initials: K
authors.lastname: Ogasahara
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D049268:Positron-Emission Tomography; D012008:Recurrence; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine